FI4066821T3 - Neratinibimaleaatin tablettiformulaatioita - Google Patents

Neratinibimaleaatin tablettiformulaatioita Download PDF

Info

Publication number
FI4066821T3
FI4066821T3 FIEP22169771.7T FI22169771T FI4066821T3 FI 4066821 T3 FI4066821 T3 FI 4066821T3 FI 22169771 T FI22169771 T FI 22169771T FI 4066821 T3 FI4066821 T3 FI 4066821T3
Authority
FI
Finland
Prior art keywords
weight
components
crospovidone
neratinib maleate
microcrystalline cellulose
Prior art date
Application number
FIEP22169771.7T
Other languages
English (en)
Finnish (fi)
Inventor
Muhammad Ashraf
Krishnendu Ghosh
Chimanlall Goolcharran
Mainuddin Mahmud
Arwinder Singh Nagi
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI4066821(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Application granted granted Critical
Publication of FI4066821T3 publication Critical patent/FI4066821T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FIEP22169771.7T 2009-11-09 2010-11-02 Neratinibimaleaatin tablettiformulaatioita FI4066821T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25940309P 2009-11-09 2009-11-09

Publications (1)

Publication Number Publication Date
FI4066821T3 true FI4066821T3 (fi) 2025-05-13

Family

ID=43478191

Family Applications (3)

Application Number Title Priority Date Filing Date
FIEP22169771.7T FI4066821T3 (fi) 2009-11-09 2010-11-02 Neratinibimaleaatin tablettiformulaatioita
FIEP10779339.0T FI2498756T4 (fi) 2009-11-09 2010-11-02 Neratinibimaleaatin tablettiformulaatiot
FIC20250029C FIC20250029I1 (fi) 2009-11-09 2025-08-29 neratinibi

Family Applications After (2)

Application Number Title Priority Date Filing Date
FIEP10779339.0T FI2498756T4 (fi) 2009-11-09 2010-11-02 Neratinibimaleaatin tablettiformulaatiot
FIC20250029C FIC20250029I1 (fi) 2009-11-09 2025-08-29 neratinibi

Country Status (23)

Country Link
US (2) US8518446B2 (https=)
EP (4) EP4066821B1 (https=)
JP (3) JP5835883B2 (https=)
CN (2) CN102724970B (https=)
AR (2) AR078952A1 (https=)
AU (1) AU2010316683B2 (https=)
CA (1) CA2780428C (https=)
CY (1) CY1122330T1 (https=)
DK (2) DK2498756T4 (https=)
ES (3) ES2757882T5 (https=)
FI (3) FI4066821T3 (https=)
FR (1) FR25C1035I1 (https=)
HR (2) HRP20192026T4 (https=)
HU (3) HUE046606T2 (https=)
LT (3) LT4066821T (https=)
NZ (1) NZ599763A (https=)
PL (2) PL4066821T3 (https=)
PT (2) PT4066821T (https=)
RS (2) RS59599B2 (https=)
SI (2) SI2498756T2 (https=)
SM (2) SMT202500153T1 (https=)
TW (1) TWI466690B (https=)
WO (1) WO2011055303A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
ES2364495T3 (es) 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9439897B2 (en) 2007-11-06 2016-09-13 Immunolight, Llc Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN105147713A (zh) 2008-08-04 2015-12-16 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
SG174382A1 (en) 2009-04-06 2011-11-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
CN102724962B (zh) * 2009-11-09 2017-05-17 惠氏有限责任公司 包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途
AU2010316683B2 (en) * 2009-11-09 2015-10-08 Wyeth Llc Tablet formulations of neratinib maleate
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
ES2643403T3 (es) 2011-12-28 2017-11-22 Global Blood Therapeutics, Inc. Compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
MX379235B (es) 2013-03-15 2025-03-11 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina.
WO2014150258A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9818967B2 (en) * 2013-06-28 2017-11-14 Universal Display Corporation Barrier covered microlens films
CN104337782A (zh) * 2013-08-02 2015-02-11 山东新时代药业有限公司 一种甲磺酸伊马替尼片剂
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CN114181195A (zh) 2014-02-07 2022-03-15 全球血液疗法股份有限公司 一种化合物的结晶多晶型物
WO2015123699A1 (en) 2014-02-17 2015-08-20 Children's National Medical Center Method and system for providing recommendation for optimal execution of surgical procedures
US10085993B2 (en) * 2014-07-25 2018-10-02 Novartis Ag Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
WO2017003951A1 (en) * 2015-06-29 2017-01-05 Phloronol, Inc. Solid pharmaceutical compositions of brown algae
SG11201804647TA (en) 2015-12-04 2018-06-28 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN106831710A (zh) * 2015-12-07 2017-06-13 常州爱诺新睿医药技术有限公司 一种无定型来那替尼或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
CN106913529B (zh) * 2015-12-24 2020-12-04 江苏恒瑞医药股份有限公司 一种来那替尼或其可药用盐药物组合物的制备方法
CA2937365C (en) * 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
MX392941B (es) * 2016-09-07 2025-03-24 Celgene Corp Composiciones para comprimidos.
TW202332423A (zh) * 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
KR20190140011A (ko) * 2017-04-28 2019-12-18 아사나 바이오사이언시스 엘엘씨 아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형
CA3079916A1 (en) * 2017-10-24 2019-05-02 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing quinoline derivative
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
CA3168680A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) * 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US20220378788A1 (en) * 2020-04-30 2022-12-01 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
KR20230027201A (ko) * 2020-06-19 2023-02-27 아세르타 파마. 비.브이. 아칼라브루티닙 말레산염 투약 형태
CN116211859A (zh) * 2021-12-03 2023-06-06 江苏奥赛康药业有限公司 一种含有马来酸奈拉替尼的药用组合物及其制备方法
WO2023170554A1 (en) * 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
TW202345857A (zh) * 2022-03-08 2023-12-01 美商昂科斯克塞爾醫療有限責任公司 他波司他之穩定調配物
WO2024187321A1 (zh) 2023-03-10 2024-09-19 甫康（上海）健康科技有限责任公司 含有egfr抑制剂的药物组合物及其制备方法和应用
CN117298116A (zh) * 2023-08-08 2023-12-29 江苏晨泰医药科技有限公司 盐酸佐利替尼制剂
CN117427076B (zh) * 2023-12-05 2025-09-19 中国科学技术大学 来那替尼在制备预防或治疗动脉粥样硬化药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
US20050142192A1 (en) * 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
AR046544A1 (es) * 2003-10-15 2005-12-14 Wyeth Corp Administracion oral de acido [2- (8,9 - dioxo - 2,6 - diazabiciclo [5.2.0] non -1 (7) - en - 2 - il ) alquil] fosfonico yderivados
PE20060608A1 (es) * 2004-10-13 2006-08-22 Wyeth Corp Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
WO2006085168A2 (en) 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
CN101166532B (zh) * 2005-04-28 2011-06-22 惠氏公司 微粒化的他那普戈特、组合物及其制备方法
PL1948180T3 (pl) * 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
JP2007169273A (ja) * 2005-11-28 2007-07-05 Takeda Chem Ind Ltd 杵付着を改善した医薬製剤
JP2007211005A (ja) * 2006-01-16 2007-08-23 Ono Pharmaceut Co Ltd 固形製剤用組成物および固形製剤
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
CL2008000095A1 (es) * 2007-01-12 2008-05-16 Wyeth Corp Composicion de tableta en tableta que comprende una tableta central con estrogenos, un rellenador/diluyente, un rellenador/aglomerante, un componente polimerico y una capa de tableta exterior comprimida con agentes terapeuticos, un rellenador/diluyen
EP2124901B1 (en) * 2007-02-01 2017-07-19 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
JP2009089982A (ja) * 2007-10-11 2009-04-30 Ohara Yakuhin Kogyo Kk 打錠用造粒物の造粒方法
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
BRPI1015941A2 (pt) * 2009-07-02 2016-04-19 Wyeth Llc formulações de comprimido de 3-cianoquinolina e uso das mesmas.
AU2010316683B2 (en) * 2009-11-09 2015-10-08 Wyeth Llc Tablet formulations of neratinib maleate

Also Published As

Publication number Publication date
DK4066821T3 (da) 2025-04-14
TWI466690B (zh) 2015-01-01
CN102724970A (zh) 2012-10-10
ES2757882T5 (es) 2023-05-10
ES2757882T3 (es) 2020-04-30
HUE071632T2 (hu) 2025-09-28
RS66797B1 (sr) 2025-06-30
TW201138774A (en) 2011-11-16
LT4066821T (lt) 2025-05-12
US8790708B2 (en) 2014-07-29
US8518446B2 (en) 2013-08-27
SI2498756T2 (sl) 2023-04-28
EP4570242A3 (en) 2025-08-20
EP2498756A1 (en) 2012-09-19
EP2498756B1 (en) 2019-09-04
HRP20192026T4 (hr) 2023-03-31
DK2498756T3 (da) 2019-11-25
HRP20250604T1 (hr) 2025-07-18
DK2498756T4 (da) 2023-03-20
CN103893140B (zh) 2016-06-01
RS59599B2 (sr) 2023-03-31
ES2998766T3 (en) 2025-02-21
JP2015091882A (ja) 2015-05-14
NZ599763A (en) 2014-06-27
US20140004184A1 (en) 2014-01-02
HUS2500035I1 (hu) 2025-09-28
EP4570242A2 (en) 2025-06-18
ES3029208T3 (en) 2025-06-23
FR25C1035I1 (fr) 2025-11-21
LTPA2025531I1 (https=) 2025-09-10
SI4066821T1 (sl) 2025-06-30
AR114143A2 (es) 2020-07-29
CA2780428A1 (en) 2011-05-12
SI2498756T1 (sl) 2020-01-31
PT4066821T (pt) 2025-06-03
EP4066821A1 (en) 2022-10-05
LT2498756T (lt) 2019-12-10
PL2498756T3 (pl) 2020-03-31
HUE046606T2 (hu) 2020-03-30
CN103893140A (zh) 2014-07-02
JP5835883B2 (ja) 2015-12-24
EP2498756B2 (en) 2023-02-15
CA2780428C (en) 2018-02-13
PL4066821T3 (pl) 2025-08-11
EP4066821B1 (en) 2025-03-05
AU2010316683B2 (en) 2015-10-08
PL2498756T5 (pl) 2023-04-17
WO2011055303A1 (en) 2011-05-12
US20110111018A1 (en) 2011-05-12
CY1122330T1 (el) 2021-01-27
FI2498756T4 (fi) 2023-03-22
SMT202500153T1 (it) 2025-05-12
RS59599B1 (sr) 2020-01-31
JP2011098964A (ja) 2011-05-19
HRP20192026T1 (hr) 2020-02-07
SMT201900632T1 (it) 2020-01-14
EP3566697B1 (en) 2024-09-11
AR078952A1 (es) 2011-12-14
JP2017075192A (ja) 2017-04-20
CN102724970B (zh) 2014-06-25
PT2498756T (pt) 2019-11-26
AU2010316683A1 (en) 2012-05-24
FIC20250029I1 (fi) 2025-08-29
EP3566697A1 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
FI4066821T3 (fi) Neratinibimaleaatin tablettiformulaatioita
JP2011098964A5 (https=)
JP6150777B2 (ja) 固体薬学的組成物およびそれらの生産のためのプロセス
ES2465478T3 (es) Composiciones farmacéuticas que comprenden brivaracetam
KR101573889B1 (ko) 속효성과 지속성을 동시에 갖는 약제학적 조성물
ES2311442T1 (es) Dosis en forma oral.
CA2440588A1 (en) Chronotherapeutic dosage forms
ES2435943T3 (es) Formulaciones de vildagliptina
JP2015533129A (ja) チカグレロルを含む固形経口医薬製剤
AU2010259003A1 (en) A thrombin receptor antagonist and clopidogrel fixed dose tablet
CA2696977A1 (en) Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
WO2013077824A1 (en) Preparation process for a formulation comprising metformin
RU2007133793A (ru) Составы с контролируемым высвобождением альфузозина
ES2673870T3 (es) Formulación de dosificación oral sólida de [(1S)-1-{[(2S,4R)-4-(7-cloro-4-metoxiisoquinolin-1-iloxi)-2-({(1R,2S)-1-[(ciclopropilsulfonil) carbamoil]-2-etenilciclopropil} carbamoil) pirrolidin-1-il] carbonil}-2,2-dimetil-propil] carbamato de 1,1-dimetiletilo
EP3383402B1 (en) Pharmaceutical composition comprising darunavir and method for the preparation thereof
AU2012233203A1 (en) Solid preparation
WO2023128898A1 (en) Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients
CN101217943A (zh) 药物活性组分的缓释剂型
JP6344678B2 (ja) テルミサルタン含有製剤及びその製造方法
CN113995727A (zh) 一种5型磷酸二酯酶抑制剂片剂及其制备方法
EA051960B1 (ru) Фармацевтическая композиция бемпедоевой кислоты
HK40018352B (zh) 含葡萄糖激酶激活剂和α-葡萄糖苷酶抑制剂的药物组合及其制备方法和用途
HRP20231200T1 (hr) Kombinacija fiksne doze memantina i donepezila s trenutnim otpuštanjem
CN101478983A (zh) 含有对水分敏感的药物和第二药物的组合的稳定制剂及其制造方法
NZ615452B2 (en) Solid preparation containing 6-((7s)-7-hydroxy-6,7-dihydro-5h-pyrrolo-[1,2-c]imidazol-7-yl)-n-methyl-2-naphthamide